We can’t show the full text here under this license. Use the link below to read it at the source.
Number Needed to Treat and Cost Per Responder Analysis of Anti-CGRP Monoclonal Antibodies for Migraine Prevention in Adults for Whom Prior Preventive Treatments have Failed
Number Needed to Treat and Cost for Migraine Prevention Using Anti-CGRP Antibodies in Adults Who Didn’t Respond to Previous Treatments
AI simplified
Abstract
The (NNT) for achieving a ≥ 50% reduction in monthly migraine days (MMDs) with anti-CGRP monoclonal antibodies ranges from 2.7 to 6.0.
- All anti-CGRP monoclonal antibodies showed significantly higher rates of ≥ 50% and ≥ 75% MMD reduction compared to placebo.
- NNT for a ≥ 50% MMD reduction varied from 2.7 for eptinezumab 300 mg to 6.0 for erenumab 140 mg.
- For a ≥ 75% MMD reduction, NNT ranged from 6.0 for eptinezumab 300 mg to 16.2 for fremanezumab 675 mg/q.
- The quarterly (CPR) for achieving a ≥ 50% reduction varied from £4647 for eptinezumab 100 mg to £7009 for erenumab 140 mg.
- For achieving a ≥ 75% reduction, CPR ranged from £9850 for eptinezumab 100 mg to £21,862 for fremanezumab 675 mg/q.
AI simplified
Key numbers
2.7
for ≥ 50% Reduction
for eptinezumab 300 mg to achieve a ≥ 50% reduction in monthly migraine days.
£4,647
Cost per ≥ 50% Responder
Cost for eptinezumab 100 mg per responder achieving ≥ 50% reduction.
6.0
for ≥ 75% Reduction
for eptinezumab 300 mg to achieve a ≥ 75% reduction in monthly migraine days.